LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

Status:
Terminated

Trial end date:
2011-10-01

Target enrollment:

Participant gender:

This study will assess the efficacy and safety of LFF269 compared to placebo after treatment in subjects with essential hypertension.

Phase 2

Novartis Pharmaceuticals

Eplerenone
Spironolactone